Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Jeff Ubben, ValueAct Now Own 9.7% of Rockwell Collins

Jeff Ubben, ValueAct: In a filing with the Securities and Exchange Commission, Jeffrey Ubben’s hedge fund, Valueact Capital, disclosed buying shares of Rockwell Collins, Inc. (NYSE:COL). The hedge fund reported ownership of some 13.1 million shares of the company, up from the previously disclosed amount of 11.2 million shares. The value of the current stake held by ValueAct amounts to almost $901.3 million. The position represents some 9.7% of the company.


Last week, Rockwell Collins posted its guidance for the whole fiscal year 2013. In this way, the company forecasts revenue in the range $4.5 billion to $4.6 billion, while earnings per share is expected to be between $4.30 and $4.50. Rockwell Collins is a company specialized in manufacturing, design and support of aviation electronics and communications for various commercial and military clients around the world.

Aside from Ubben, some other “hedgies” out of those tracked by Insider Monkey also disclosed ownership of shares of Rockwell Collins. As follows, Thomas Steyer’s Farallon Capital reported owning of some 1.6 million shares of the company, while the stake held by Adage Capital Management, managed by Phill Gross and Robert Atchinson, contained around 1.1 million shares at the end of last quarter. John Burbank’s Passport Capital and D. E. Shaw’s D E Shaw & Co have less significant positions, which involve about 887,000 and 681,900 shares respectively.

Recommended Reading:

James Flynn, Deerfield Buy RNA-Themed Prosensa

Dmitry Balyasny’s Walter Energy Bet Shows Some Don’t Think Coal Is Dead Yet

Richard Perry, Perry Capital Cut 9M J.C. Penney Shares

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!